HCLTech gains 3% on renewing $278 million deal with Germany’s apoBank

HCLTech also extended its partnership with the global medtech firm Olympus.

Trade

• Watchlist
• Portfolio
• Message
• Set Alert

 

 

Choose Stock Exchange: BSE LIVE NSE LIVE

26 Aug, 2025 12:21

Volume

Todays L/H

More

×

Shares of HCLTech rose around 3 percent on June 12 after the company announced renewing a $278 million deal with Germany’s apoBank for a period of 7.5 years.

The information technology major will help apoBank with an outcome-oriented managed services model to deliver fast and secure banking services to its customers.

At 09.33 am, shares of HCLTech were trading at Rs 1,449.20 on the NSE.

Brokerage firm Morgan Stanley also sees this deal win for HCLTech in positive light. The brokerage feels that the deal win shows continuing large deal win momentum in the financial services vertical for HCLTech.

Morgan Stanley, which has an 'overweight' call on HCLTech with a price target of Rs 1,650, also remarked on HCLTech's significant expansion of an existing client relationship.

Follow our live blog for all the market action

Meanwhile, the brokerage also feels more confident on HCLTech's ability to achieve its full year revenue guidance as large deals like these provide comfort.

Furthermore, HCLTech also extended its partnership with the global medtech firm Olympus to enable advanced and affordable healthcare for patients through cutting-edge engineering technologies.

The two companies share a decade-long partnership in engineering and R&D, spanning product engineering, software engineering, product sustenance, and risk and regulatory services.

On that account, HCLTech will establish a dedicated product innovation center in Hyderabad to serve Olympus' operations across the US, Europe, the Middle East, and Africa.

Disclaimer: The views and investment tips expressed by investment experts on Moneycontrol.com are their own and not those of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.